Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03190174 · ClinicalTrials.gov registry record · Phase 1
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
A Phase 1 study, sponsored by Sarcoma Oncology Research Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT03190174 is a Phase 1 study that has completed, run by Sarcoma Oncology Research Center. The registered enrollment target is 34 participants.
The verdict
NCT03190174, a Phase 1 study, has completed, sponsored by Sarcoma Oncology Research Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in advanced Ewing's sarcoma, perivascular epithelioid cell tumor (PEComa), epithelioid sarcoma, desmoid tumor, chordoma, non-small cell lung cancer, small cell lung cancer, urothelial carcinoma, melanoma, renal cell carcinoma, squamous cell carcinoma of head and neck, hepatocellular carcinoma, classical Hodgkin's lymphoma, high microsatellite instability (MSI-H)/ mismatch repair deficient (dMMR) metastatic colorectal cancer, and tumors with genetic mutations sensitive to mTOR inhibitors.
Interventions
- BIOLOGICAL Nivolumab
- DRUG Nab-Rapamycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2017-08-24 |
| Est. Completion | 2021-12-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03190174
The ClinicalTrials.gov registry entry for NCT03190174 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarcoma Oncology Research Center, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03190174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03190174 about?
NCT03190174 is a clinical study titled "Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers". This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in advanced Ewing's sarcoma, perivascular epithelioid cell tumor (PEComa), epithe...
What is the current status of trial NCT03190174?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2017-08-24. Estimated completion is 2021-12-02.
What interventions are being tested in trial NCT03190174?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Nab-Rapamycin (DRUG).
Who is sponsoring clinical trial NCT03190174?
This trial is sponsored by Sarcoma Oncology Research Center, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.